SAGE Sage Therapeutics Inc. Total Business Assets

SAGE (Sage Therapeutics, Inc) - company brandmark

Sage Therapeutics, Inc. (SAGE) relies on external contractors for drug manufacturing and testing, allowing the company to focus on brain pathology therapies. This price chart reflects the dynamics of total assets, which currently stand at 560.04. Sage Therapeutics, Inc. (SAGE) acts as a neurobiology innovator, developing treatments for postpartum depression, while management oversees the delegation of processes to third-party CROs to mitigate operational risks.

Cumulative Company Assets: Sage Therapeutics, Inc. (SAGE) for 07/04/2022 - 08/16/2025

Analytical breakdowns and data insights for company Sage Therapeutics, Inc (SAGE)

- stock value and consensus price forecast:
Market Price sagerx.com|SAGE - Price Target Chart
- market capitalization data:
Market Capitalization Sage Therapeutics Inc|SAGE - Enterprise Value
- book capitalization information:
Net Asset Value per Share Sage Therapeutics|SAGE - Company Net Assets|Market Capitalization to Book Value Ratio sagerx.com|SAGE - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Sage Therapeutics, Inc.|SAGE - Long-Term Debt to Equity|Current Liabilities to Capital Sage Therapeutics Inc|SAGE - Company Debts|Debts to Net Assets Sage Therapeutics Inc|SAGE - Company Long-Term Debts|Company Short-Term Debts Sage Therapeutics|Critical Liquidity sagerx.com
- company profitability and valuation multiples indicators:
SAGE - Net Profit
Basic company analysis:SAGE - sagerx.com
Manufactured products of Sage Therapeutics

To isolate fundamental stability from market noise, it is critical to analyze the aggregate resources combining equity and liabilities through a reverse ROA calculation, which enables real-time tracking of business scaling. By analyzing the current level of balance sheet assets, an investor can see the financial foundation that provides Sage Therapeutics, Inc. (SAGE) with generous R&D funding and the ability to retain leading neurobiologists for the development of innovative CNS therapies.

Direct competitors

Company Assets biogen.com (BIIB)|Aggregate Company Assets Neurocrine Biosciences, Inc.|Total Business Assets RGC (Regencell Bioscience Ltd)|Company Total Assets AXSM|ACAD - Company Assets|Xenon Pharmaceuticals - Cumulative Company Assets|Company Total Assets vikingtherapeutics.com VKTX|SUPN - Aggregate Company Assets|Aggregate Asset Value CPRX (Catalyst Pharma)|Denali Therapeutics Inc (DNLI) - Aggregate Company Assets|Company Assets Harmony Corp (HRMY)|Aggregate Company Assets Biohaven Ltd.|amylyx.com (AMLX) - Company Total Asset Base|Company Total Assets TRVI|Company Total Assets Praxis Precision Medicines Inc (PRAX)|Company Total Assets AVXL (Anavex Corp)|Company Balance Sheet Assets CeriBell EEG|Prothena Corporation plc - Company Total Assets|Company Assets Alector, Inc.|ANNX (Annexon) - Cumulative Company Assets|Omeros - Aggregate Asset Value|Cumulative Company Assets NGNE|ACIU (AC Immune Inc) - Aggregate Business Assets|Company Total Assets VYGR|NMRA (neumoratx.com) - Aggregate Asset Value|Company Total Assets SCLX (Scilex)|Tevogen Bio Holdings Inc. (TVGN) - Company Assets|ACOG - Aggregate Company Assets|Aggregate Asset Value CGTX (Cognition Therapeutics Inc.)|IKT: Company Total Assets|cassavasciences.com (SAVA) - Company Total Assets|Aggregate Company Assets Assertio Holdings|Coya - Total Asset Value of Company|Company Total Assets VTGN|OVID - Company Assets|Acumen Pharmaceuticals - Cumulative Company Assets|Company Total Assets cervomed.com CRVO|ATHE: Cumulative Company Assets|Clene Inc. - Aggregate Business Assets|PEPG: Company Total Assets|JUNS - Company Total Asset Base|RLMD (Relmada Therapeutics) - Company Total Assets|Cumulative Company Assets annovisbio.com (ANVS)|Aggregate Company Assets Grace Therapeutics, Inc. (GRCE)|Company Total Asset Base Firefly Neuroscience, Inc.|Klotho Neurosciences - Cumulative Company Assets|Aggregate Asset Value NRSN|Reviva Pharmaceuticals - Company Total Assets|Company Total Asset Base MetaVia Inc MTVA|NeurAxis (NRXS) - Aggregate Company Assets|Total Business Assets HSDT|PASG (Passage Bio Inc.) - Company Total Assets|Cumulative Company Assets Neuphoria (NEUP)|Cumulative Company Assets NERV (Minerva Neurosciences)|Company Total Asset Base athira.com|Aggregate Company Assets Addex Therapeutics Ltd ADXN|Company Total Asset Base Alzamend Neuro Inc. (ALZN)|Cyclerion - Company Total Assets|PTIX - Company Total Assets|KTTA: Company Total Assets|Company Balance Sheet Assets Cortigent CRGT|ATXI (Avenue Therapeutics, Inc.) - Company Total Assets|Company Assets Brainstorm Cell Therapeutics Inc. BCLI|Aggregate Company Assets Cara Therapeutics, Inc (CARA)|Chromocell - Total Business Assets|Company Total Assets ELYM (Eliem Therapeutics Inc.)|Intra-Cellular Therapies Inc. (ITCI) - Company Assets|LBPH: Cumulative Company Assets|MRNS - Company Total Assets|NKGen (NKGN) - Aggregate Company Assets|NeuroBo Pharma - Aggregate Asset Value|Aggregate Company Assets Synaptogenix, Inc.|Company Assets trevena.com TRVN|Aggregate Company Assets Vigil Neuroscience (VIGL)|Company Total Asset Base anewmeds.com|Company Total Assets CERE (Cerevel)